What one share of Aldeyra Therapeutics holds
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity.
Aldeyra Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.38 |
|---|---|
| Cash and investments | $0.75 |
| Debt | $0.25 |
| Book value | $0.63 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2013 | — | −$17.61 | — | — | — | — |
| 2014 | — | −$3.09 | $0.00 | −$1.24 | — | $1.13 |
| 2015 | — | −$1.40 | $0.01 | −$1.09 | — | $2.56 |
| 2016 | — | −$1.65 | $0.00 | −$1.34 | — | $1.72 |
| 2017 | — | −$1.40 | $0.00 | −$1.21 | — | $2.07 |
| 2018 | — | −$1.79 | $0.01 | −$1.39 | — | $3.30 |
| 2019 | — | −$2.24 | $0.00 | −$1.66 | — | $1.68 |
| 2020 | — | −$1.11 | — | — | — | $1.54 |
| 2021 | — | −$1.07 | $0.00 | −$0.79 | — | $3.54 |
| 2022 | — | −$1.06 | $0.00 | −$0.97 | — | $2.58 |
| 2023 | — | −$0.64 | $0.00 | −$0.51 | — | $2.02 |
| 2024 | — | −$0.94 | — | — | — | $1.19 |
| 2025 | — | −$0.56 | — | — | — | $0.74 |
Common questions about Aldeyra Therapeutics
How much does one share of Aldeyra Therapeutics earn?
Over the last 12 months, Aldeyra Therapeutics lost $0.38 for each share.
Does Aldeyra Therapeutics pay a dividend?
Aldeyra Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Aldeyra Therapeutics’s book value per share?
Aldeyra Therapeutics’s book value is $0.63 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Aldeyra Therapeutics have?
Each share of Aldeyra Therapeutics has $0.75 of cash and investments and $0.25 of debt, as of June 30, 2026.
Has Aldeyra Therapeutics bought back shares?
Aldeyra Therapeutics’s share count rose about 6920% from 2013 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.